Takeda Pharmaceutical Co (TKPHF) Stock Forecast & Price Target

Compare

35 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TKPHF Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Takeda

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TKPHF Stock 12 Month Forecast

Average Price Target

$34.10

▲(20.75% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Takeda Pharmaceutical Co in the last 3 months. The average price target is $34.10 with a high forecast of $37.08 and a low forecast of $29.79. The average price target represents a 20.75% change from the last price of $28.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","31":"$31","38":"$38","27.5":"$27.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37.0776,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$37.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.7945,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,27.5,31,34.5,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29,29.621353846153845,30.242707692307693,30.864061538461538,31.485415384615383,32.10676923076923,32.728123076923076,33.34947692307692,33.970830769230766,34.59218461538461,35.21353846153846,35.83489230769231,36.45624615384615,{"y":37.0776,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29,29.392307692307693,29.784615384615385,30.176923076923078,30.56923076923077,30.961538461538463,31.353846153846156,31.746153846153845,32.13846153846154,32.53076923076923,32.92307692307693,33.315384615384616,33.70769230769231,{"y":34.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29,29.061115384615384,29.122230769230768,29.183346153846152,29.24446153846154,29.305576923076924,29.366692307692308,29.42780769230769,29.488923076923076,29.55003846153846,29.611153846153847,29.67226923076923,29.733384615384615,{"y":29.7945,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.88,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$37.08

Average Price Target$34.10

Lowest Price Target$29.79

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$34.43→$33.11

Buy

17.23%

Upside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Bryce Generon

TR | OpenAI - 4o

$30.34→$29.07

Hold

2.95%

Upside

Reiterated

10/11/25

AI Generated ArticleAI Generated Article

Miki Sogi

Bernstein

$29.79

Hold

5.50%

Upside

Reiterated

10/10/25

Bernstein Reaffirms Their Hold Rating on Takeda Pharmaceutical Co (TKPHF)

Shinichiro Muraoka

Morgan Stanley

$37.08

Buy

31.29%

Upside

Reiterated

09/23/25

Morgan Stanley Reaffirms Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Koichi Mamegano

Bank of America Securities

$36.42

Buy

28.95%

Upside

Reiterated

09/08/25

Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating

Hiroyuki Matsubara

Nomura

$35.75→$35.09

Buy

24.26%

Upside

Reiterated

06/12/25

Nomura Keeps Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Michael Nedelcovych

TD Cowen

$34

Buy

20.39%

Upside

Reiterated

05/21/25

Kelly Shi

Jefferies

$36.42→$33.77

Buy

19.57%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (Other OTC: TKPHF), Opus Genetics (NASDAQ: IRD) and CareCloud (NASDAQ: CCLD)

Unknown Analyst

Bloomberg Ind.

Not Ranked

Bloomberg Ind.

$36.42→$33.77

Buy

19.57%

Upside

Reiterated

05/08/25

Seiji Wakao

J.P. Morgan

$28.47→$29.79

Hold

5.50%

Upside

Reiterated

03/27/25

Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,500 at JPMorganJPMorgan analyst Seiji Wakao raised the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY4,500.00 (from JPY4,300.00) while maintaining a Neutral rating.

Zhijie Zhao

CLSA

$38.4

Buy

35.98%

Upside

Initiated

03/13/25

CLSA Starts Takeda Pharmaceutical (4502:JP) (TAK) at Outperform (2)CLSA analyst Zhijie Zhao initiates coverage on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) with a Outperform (2) rating and a price target of JPY5,800.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$34.43→$33.11

Buy

17.23%

Upside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Bryce Generon

TR | OpenAI - 4o

$30.34→$29.07

Hold

2.95%

Upside

Reiterated

10/11/25

AI Generated ArticleAI Generated Article

Miki Sogi

Bernstein

$29.79

Hold

5.50%

Upside

Reiterated

10/10/25

Bernstein Reaffirms Their Hold Rating on Takeda Pharmaceutical Co (TKPHF)

Shinichiro Muraoka

Morgan Stanley

$37.08

Buy

31.29%

Upside

Reiterated

09/23/25

Morgan Stanley Reaffirms Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Koichi Mamegano

Bank of America Securities

$36.42

Buy

28.95%

Upside

Reiterated

09/08/25

Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating

Hiroyuki Matsubara

Nomura

$35.75→$35.09

Buy

24.26%

Upside

Reiterated

06/12/25

Nomura Keeps Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Michael Nedelcovych

TD Cowen

$34

Buy

20.39%

Upside

Reiterated

05/21/25

Kelly Shi

Jefferies

$36.42→$33.77

Buy

19.57%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (Other OTC: TKPHF), Opus Genetics (NASDAQ: IRD) and CareCloud (NASDAQ: CCLD)

Unknown Analyst

Bloomberg Ind.

Not Ranked

Bloomberg Ind.

$36.42→$33.77

Buy

19.57%

Upside

Reiterated

05/08/25

Seiji Wakao

J.P. Morgan

$28.47→$29.79

Hold

5.50%

Upside

Reiterated

03/27/25

Zhijie Zhao

CLSA

$38.4

Buy

35.98%

Upside

Initiated

03/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Takeda Pharmaceutical Co

1 Month

xxx

Success Rate

2/2 ratings generated profit

Average Return

+5.55%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +5.55% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+11.80%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +11.80% per trade.

1 Year

Koichi MameganoBank of America Securities

Success Rate

4/7 ratings generated profit

Average Return

+2.27%

reiterated a buy rating last month

Copying Koichi Mamegano's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +2.27% per trade.

2 Years

xxx

Success Rate

4/7 ratings generated profit

Average Return

+1.67%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +1.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TKPHF Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TKPHF has received 3 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. TKPHF average Analyst price target in the past 3 months is 34.10.

Each month's total comprises the sum of three months' worth of ratings.

TKPHF Financial Forecast

TKPHF Earnings Forecast

Next quarter’s earnings estimate for TKPHF is $0.23 with a range of $0.14 to $0.33. The previous quarter’s EPS was $0.53. TKPHF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TKPHF has Preformed in-line its overall industry.

TKPHF Sales Forecast

Next quarter’s sales forecast for TKPHF is $7.78B with a range of $7.49B to $8.31B. The previous quarter’s sales results were $7.33B. TKPHF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TKPHF has Preformed in-line its overall industry.

TKPHF Stock Forecast FAQ

What is TKPHF’s average 12-month price target, according to analysts?

Based on analyst ratings, Takeda Pharmaceutical Co Ltd’s 12-month average price target is 34.10.

What is TKPHF’s upside potential, based on the analysts’ average price target?

Takeda Pharmaceutical Co Ltd has 20.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TKPHF a Buy, Sell or Hold?

Takeda Pharmaceutical Co Ltd has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is Takeda Pharmaceutical Co Ltd’s price target?

The average price target for Takeda Pharmaceutical Co Ltd is 34.10. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.08 ,the lowest forecast is $29.79. The average price target represents 20.75% Increase from the current price of $28.24.

What do analysts say about Takeda Pharmaceutical Co Ltd?

Takeda Pharmaceutical Co Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of TKPHF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Takeda Pharmaceutical Co (TKPHF) Stock Forecast & Price Target

TKPHF Analyst Ratings

TKPHF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Takeda Pharmaceutical Co

TKPHF Analyst Recommendation Trends

TKPHF Financial Forecast

TKPHF Earnings Forecast

TKPHF Sales Forecast

TKPHF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts